Role of gut microbiome in regulating the effectiveness of metformin in reducing colorectal cancer in type 2 diabetes

doi:10.12998/wjcc.v8.i24.6213

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 24

This Article

(268)

(273)

(0)

(17)

(1)

(8682)

(18)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Clin Cases. Dec 26, 2020; 8(24): 6213-6228
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6213

Table 3 Summary of alteration of gut microbiota by metformin in patients with type 2 diabetes mellitus that may affect colorectal cancer from 2014 to 2020

Status	Classification	Metformin-related		CRC-related
Status	Classification	Metformin-related		Multiple polypoid	Stage 0/pTis	Stage SI/II	Stage SIII/IV
Increased¹	Phyla	Bacteroidetes, Actinobacteria, Proteobacteria	Proteobacteria		Firmicutes, Fusobacteria Bacteroidetes	Firmicutes, Fusobacteria Bacteroidetes	Firmicutes, Fusobacteria Bacteroidetes
	Genus	Bacteroides, Streptococcus, Collinsella, Escherichia, Clostridium, Subdoligranulum			F. nucleatum	F. nucleatum	F. nucleatum
	Species	Escherichia spp., Anaerostipes, Blautia, Akkermansia muciniphila	Atopobium parvulum		Solobacterium moorei, Lactobacillus sanfranciscensis, Gemella morbillorum, Actinomyces odontolyticus, Desulfovibrio longreachensis, Phascolarctobacterium succinatutens	Solobacterium moorei, Peptostreptococcus stomatis, Peptostreptococcus anaerobius, Parvimonas micra, Gemella morbillorum	Solobacterium moorei, Peptostreptococcus stomatis, Peptostreptococcus anaerobius, Lactobacillus sanfranciscensis, Parvimonas micra, Gemella morbillorum
Decreased¹	Phyla	Firmicutes, Verrucomicrobia
	Genus	Faecalibacterium, Ruminococcus			Bifidobacterium
	Species	Intestinibacter spp., Intestinibacter bartlettii., Alistipes, Oscillibacter, un-Ruminococcaceae
Other axes	Increased¹	Lactobacillus (Glucose-SGLT1-Sensing Glucoregulatory Pathway)
		E. coli, Proteobacteria (Host-GUDCA-intestinal FXR axis)
	Decreased¹	Bacteroides fragilis (B. fragilis–GUDCA–intestinal FXR axis)

¹Compared with metformin untreated. CRC: Colorectal cancer; T2DM: Type 2 diabetes mellitus.

Full Size Table

Citation: Huang QY, Yao F, Zhou CR, Huang XY, Wang Q, Long H, Wu QM. Role of gut microbiome in regulating the effectiveness of metformin in reducing colorectal cancer in type 2 diabetes. World J Clin Cases 2020; 8(24): 6213-6228
URL: https://www.wjgnet.com/2307-8960/full/v8/i24/6213.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i24.6213

Huang QY, Yao F, Zhou CR, Huang XY, Wang Q, Long H, Wu QM. Role of gut microbiome in regulating the effectiveness of metformin in reducing colorectal cancer in type 2 diabetes. World J Clin Cases 2020; 8(24): 6213-6228 [PMID: 33392303 DOI: 10.12998/wjcc.v8.i24.6213]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.